Reassessing human MHC-I genetic diversity in T cell studies
Abstract The Major Histocompatibility Complex class I (MHC-I) system plays a vital role in immune responses by presenting antigens to T cells. Allele specific technologies, including recombinant MHC-I technologies, have been extensively used in T cell analyses for COVID-19 patients and are currently...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-04-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-024-58777-2 |
| _version_ | 1797219829954904064 |
|---|---|
| author | Roderick C. Slieker Daniël O. Warmerdam Maarten H. Vermeer Remco van Doorn Mirjam H. M. Heemskerk Ferenc A. Scheeren |
| author_facet | Roderick C. Slieker Daniël O. Warmerdam Maarten H. Vermeer Remco van Doorn Mirjam H. M. Heemskerk Ferenc A. Scheeren |
| author_sort | Roderick C. Slieker |
| collection | DOAJ |
| description | Abstract The Major Histocompatibility Complex class I (MHC-I) system plays a vital role in immune responses by presenting antigens to T cells. Allele specific technologies, including recombinant MHC-I technologies, have been extensively used in T cell analyses for COVID-19 patients and are currently used in the development of immunotherapies for cancer. However, the immense diversity of MHC-I alleles presents challenges. The genetic diversity serves as the foundation of personalized medicine, yet it also poses a potential risk of exacerbating healthcare disparities based on MHC-I alleles. To assess potential biases, we analysed (pre)clinical publications focusing on COVID-19 studies and T cell receptor (TCR)-based clinical trials. Our findings reveal an underrepresentation of MHC-I alleles associated with Asian, Australian, and African descent. Ensuring diverse representation is vital for advancing personalized medicine and global healthcare equity, transcending genetic diversity. Addressing this disparity is essential to unlock the full potential of T cells for enhancing diagnosis and treatment across all individuals. |
| first_indexed | 2024-04-24T12:39:52Z |
| format | Article |
| id | doaj.art-db6bb0c4084a42c19c01bc85581e798a |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-24T12:39:52Z |
| publishDate | 2024-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-db6bb0c4084a42c19c01bc85581e798a2024-04-07T11:19:25ZengNature PortfolioScientific Reports2045-23222024-04-011411710.1038/s41598-024-58777-2Reassessing human MHC-I genetic diversity in T cell studiesRoderick C. Slieker0Daniël O. Warmerdam1Maarten H. Vermeer2Remco van Doorn3Mirjam H. M. Heemskerk4Ferenc A. Scheeren5Department of Cell and Chemical Biology, Leiden University Medical CenterCentre for Future Affordable & Sustainable Therapy Development (FAST)Department of Dermatology, Leiden University Medical CenterDepartment of Dermatology, Leiden University Medical CenterDepartment of Hematology, Leiden University Medical CenterDepartment of Dermatology, Leiden University Medical CenterAbstract The Major Histocompatibility Complex class I (MHC-I) system plays a vital role in immune responses by presenting antigens to T cells. Allele specific technologies, including recombinant MHC-I technologies, have been extensively used in T cell analyses for COVID-19 patients and are currently used in the development of immunotherapies for cancer. However, the immense diversity of MHC-I alleles presents challenges. The genetic diversity serves as the foundation of personalized medicine, yet it also poses a potential risk of exacerbating healthcare disparities based on MHC-I alleles. To assess potential biases, we analysed (pre)clinical publications focusing on COVID-19 studies and T cell receptor (TCR)-based clinical trials. Our findings reveal an underrepresentation of MHC-I alleles associated with Asian, Australian, and African descent. Ensuring diverse representation is vital for advancing personalized medicine and global healthcare equity, transcending genetic diversity. Addressing this disparity is essential to unlock the full potential of T cells for enhancing diagnosis and treatment across all individuals.https://doi.org/10.1038/s41598-024-58777-2 |
| spellingShingle | Roderick C. Slieker Daniël O. Warmerdam Maarten H. Vermeer Remco van Doorn Mirjam H. M. Heemskerk Ferenc A. Scheeren Reassessing human MHC-I genetic diversity in T cell studies Scientific Reports |
| title | Reassessing human MHC-I genetic diversity in T cell studies |
| title_full | Reassessing human MHC-I genetic diversity in T cell studies |
| title_fullStr | Reassessing human MHC-I genetic diversity in T cell studies |
| title_full_unstemmed | Reassessing human MHC-I genetic diversity in T cell studies |
| title_short | Reassessing human MHC-I genetic diversity in T cell studies |
| title_sort | reassessing human mhc i genetic diversity in t cell studies |
| url | https://doi.org/10.1038/s41598-024-58777-2 |
| work_keys_str_mv | AT roderickcslieker reassessinghumanmhcigeneticdiversityintcellstudies AT danielowarmerdam reassessinghumanmhcigeneticdiversityintcellstudies AT maartenhvermeer reassessinghumanmhcigeneticdiversityintcellstudies AT remcovandoorn reassessinghumanmhcigeneticdiversityintcellstudies AT mirjamhmheemskerk reassessinghumanmhcigeneticdiversityintcellstudies AT ferencascheeren reassessinghumanmhcigeneticdiversityintcellstudies |